Cooler Dialysis and Liver Perfusion and Function
Evaluation of the Effects of Cooler Dialysate on Liver Perfusion, Endotoxemia and Uremic Toxin Handling in Hemodialysis Patients
1 other identifier
interventional
16
1 country
1
Brief Summary
Having hemodialysis affects the blood supply to various organs in the body including the heart and the brain. With time, these effects build up and can affect the way these organs function. The investigators have previously shown that the liver (a key organ which works to help clean the blood, make proteins and turn all your food into energy) is also affected. One of the ways to help protect organs from injury due to dialysis has been cooling during dialysis. The investigators want to examine whether cooling during dialysis protects the blood supply to the liver. CT imaging will be used to measure this blood supply during hemodialysis with standard and cooler settings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 16, 2016
CompletedFirst Posted
Study publicly available on registry
December 20, 2016
CompletedStudy Start
First participant enrolled
February 8, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 4, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
May 4, 2018
CompletedAugust 17, 2018
August 1, 2018
1.2 years
December 16, 2016
August 16, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Change in regional liver perfusion in mls/min/100g from baseline to peak stress during dialysis (3 hours into the dialysis session) with standard versus cooler dialysate temperature.
2 years
Secondary Outcomes (8)
Change in global liver perfusion in mls/min/100g pre, during and post-dialysis with cooler dialysate
2 years
ICG clearance rate pre, during and post-dialysis with cooler vs standard dialysate
2 years
Contribution of portal venous flow to hepatic perfusion (PV fraction) pre, during and post-dialysis with cooler vs standard dialysate
2 years
Endotoxin levels with cooler vs standard dialysate
2 years
Troponin T levels with cooler vs standard dialysate
2 years
- +3 more secondary outcomes
Study Arms (2)
Standard Dialysis
ACTIVE COMPARATORPatient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
Cooler Dialysis
EXPERIMENTALPatient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
Interventions
Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
Having dialysis at a standard temperature (36.5 degrees Celsius)
Eligibility Criteria
You may qualify if:
- Be able to provide informed consent
- Age greater than 18 years
- Hemodialysis for at least 3 months
- No significant residual renal function (\<250mls urine/day)
You may not qualify if:
- Chronic liver disease of any stage
- Chronic intestinal disease excluding Irritable Bowel Syndrome (IBS)
- Previous liver transplant or liver resection
- Previous Transjugular Portosystemic Shunt (TIPSS) insertion
- Active infection or malignancy
- Pregnant, breastfeeding or intending pregnancy
- Unable to give consent or understand written information
- Diabetic and experiencing hypoglycemia during dialysis within the last 2 months
- Known allergy/intolerance to contrast agent or iodides
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chris McIntyrelead
Study Sites (1)
London Health Sciences Centre
London, Ontario, Canada
Study Officials
- PRINCIPAL INVESTIGATOR
Chris W McIntyre, PhD
Western University, Canada
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Neither subjects nor the investigator at the study visits will be blinded; however, analysis of imaging data will be performed with the operator blinded to allocation.
- Purpose
- OTHER
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Medicine, UWO
Study Record Dates
First Submitted
December 16, 2016
First Posted
December 20, 2016
Study Start
February 8, 2017
Primary Completion
May 4, 2018
Study Completion
May 4, 2018
Last Updated
August 17, 2018
Record last verified: 2018-08
Data Sharing
- IPD Sharing
- Will not share